Adjuvant trastuzumab for breast cancer:Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Younis, Tallal and Skedgel, Chris ORCID: https://orcid.org/0000-0003-4989-8846 (2011) Adjuvant trastuzumab for breast cancer:Uncertainties in clinical and economic evidence following early stopping of the HERA trial. PharmacoEconomics, 29 (5). pp. 361-365. ISSN 1170-7690

Full text not available from this repository. (Request a copy)

Item Type:	Article
Uncontrolled Keywords:	antibodies, monoclonal, humanized,antineoplastic agents,breast neoplasms,chemotherapy,cost-benefit analysis,disease-free survival,early termination of clinical trials,female,humans,randomized controlled trials as topic,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	03 Feb 2015 13:14
Last Modified:	18 Jun 2026 16:41
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51930
DOI:	10.2165/11588350-000000000-00000

Actions (login required)

View Item